• FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes

    7 days ago - By Xconomy

    A type 2 diabetes drug marketed by Boehringer Ingelheim and Eli Lilly has fallen short of a bid to expand the medicine's approval to patients who have type 1 diabetes. The FDA on Friday rejected the application for the drug, empagliflozin , for use in addition to insulin as a treatment for type 1 diabetes in adults. Boehringer Ingelheim and Lilly did not detail the agency's rationale for denying the application. Last November, an FDA advisory committee voted 14 to 2 against recommending approval of the drug, saying the drug's benefits do not outweigh its safety risks. Type...
    Read more ...